“Skin Clearance, Duration of Treatment-free Interval, and Safety of Tapinarof Cream 1% Once Daily: Results from ADORING 3, a 48-week Phase 3 Trial in Adults and Children Down to 2 Years of Age with Atopic Dermatitis”, J of Skin, vol. 9, no. 2, p. s553, Mar. 2025, doi: 10.25251/skin.10.supp.553.